NEXEL

Biotechnology Research • Magokdong-ro, 8F, Korea, Republic of • 21-50 Employees

Company overview

Headquarters	Magokdong-ro, 8F, Gangseo-gu, 07802, KR
Phone number	+82220888886
Website	nexel.co.kr
SIC	283
Keywords	Drug Screening, Drug Development, Stem Cell, Fibrosis, Cell Products, Human Cell Products, Protein Therapy, Drug Toxicity Screening
Founded	2012
Employees	21-50
Socials

Key Contact at NEXEL

Choongseong Han

Ceo

NEXEL Email Formats

NEXEL uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	45.6%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	22.3%
{first name}@company.com	john@company.com	15.1%
{first name}{last name}@company.com	johndoe@company.com	9.8%
{first name}_{last name}@company.com	john_doe@company.com	7.2%

About NEXEL

NEXEL Co., Ltd. spun off from Korea University in 2012 with its proprietary stem cell technology and by the end of 2017 has introducedHEPATOSIGHT-S and CARDIOSIGHT-S to the market (https://www.nexel.co.kr/private-office). These fully functional human cell products can currently be used for a variety of research, including drug screening and toxicity tests. During our research with the stem cell, we were lucky enough to stumble upon a molecule with a significant anti-fibrotic effect. Nexel has carried out various studies to optimize its stability, manufacturability, and efficacy by modifying its structure in collaboration with respected CROs in South Korea. The new drug candidate was named NP-011 (https://www.nexel.co.kr/open-space) and has 4-folds higher anti-fibrotic effect compared to its parent molecule. The primary indication for NP-011 is NASH and Liver Fibrosis, and use in other fibrotic diseases are currently being evaluated. NEXEL's goal for NP-011 is to find a partner with experience and expertise for co-development and file for IND by the end of 2019 with K-FDA. If you have any questions regarding either of NEXEL's human cells or protein therapy, please feel free to contact at support@nexel.co.kr Thank you.

NEXEL revenue & valuation

Annual revenue	$2,309,985
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$7,400,000
Total funding	$18,300,000